Studies on the mechanism of GITR-modulating antitumor immunotherapy by 김일규
 
 
저 시-비 리- 경 지 2.0 한민  
는 아래  조건  르는 경 에 한하여 게 
l  저 물  복제, 포, 전송, 전시, 공연  송할 수 습니다.  
다 과 같  조건  라야 합니다: 
l 하는,  저 물  나 포  경 ,  저 물에 적 된 허락조건
 명확하게 나타내어야 합니다.  
l 저 터  허가를 면 러한 조건들  적 되지 않습니다.  
저 에 른  리는  내 에 하여 향  지 않습니다. 




저 시. 하는 원저 를 시하여야 합니다. 
비 리. 하는  저 물  리 목적  할 수 없습니다. 
경 지. 하는  저 물  개 , 형 또는 가공할 수 없습니다. 
약학박사학위논문 
GITR 자극을 통한 
항암 면역 치료의 작용 기전에 
대한 연구 










GITR 자극을 통한 
항암 면역 치료의 작용 기전에  
대한 연구 
 























Laboratory of Immunology 
Pharmaceutical Bioscience 
Department of Pharmacy 
The Graduate School 
Seoul National University 
 
Recently, immunotherapies using blocking monoclonal antibodies (mAbs) to immune 
check points, such as CTLA-4 and PD-1, have shown meaningful results in cancer 
clinics. Glucocorticoid-induced TNF receptor family-related protein (GITR) is a 
costimulatory molecule that has emerged as a promising target for the treatment of 
cancer. In various mouse models of tumors, GITR stimulation has displayed strong 




clinical trials. Despite the well-known antitumor effect of agonistic GITR mAbs, the 
underlying mechanism of action remains unclear. Here, I demonstrate a crucial role 
for IL-9 in antitumor immunity generated by the GITR agonistic antibody, DTA-1. 
Il4ra-/- mice were resistant to tumor growth inhibition by DTA-1, which was 
associated with reduced expression of IL-9 by CD4+ T cells. More importantly, an 
antibody against IL-9 significantly incapacitated tumor rejection by DTA-1. 
Mechanistically, GITR costimulation intrinsically enhanced IL-9 expression by CD4+ 
T cells in a TRAF6-NF-κB dependent manner, while it inhibited the generation of 
induced Treg cells in vitro and down-regulated Foxp3 expression in induced Treg cells 
in vivo.  
Furthermore, administration of anti-GITR augmented tumor-specific cytotoxic T cell 
responses in an IL-9-dependent manner, which was accompanied by increased 
maturation and cross-presentation capacity of infiltrating dendritic cells (DCs). 
Therefore, our findings demonstrate that GITR costimulation mediates antitumor 
immunity by promoting TH9 cell differentiation and thus provide a mechanism of 
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It is well-known that the immune system regulates tumor development and in 
accordance with this therapeutic strategies manipulating the immune responses 
against tumors have been recently highlighted for the treatment of cancers. However, 
immunotherapeutic approaches are faced with a difficulty in efficient induction of 
antitumor immune responses by tumor-induced suppressive microenvironments and it 
is important to simultaneously inhibit the tumor-derived suppressors for the generation 
of potent antitumor effects1. 
For increasing immune responses against tumors, it is conducted either by activating 
costimulatory receptors or by blocking coinhibitory receptors (Figure 1). Since the 
treatment of CTLA-4 blocking antibody ipilimumab for melanoma patients was 
approved by FDA in 2011, immunotherapies using monoclonal antibodies have 







Figure 1. Targeting of costimulatory or coinhibitory receptors to increase 
antitumor immune responses. 
Left, upregulation of the antitumor effector function by activating costimulatory 
receptors, such as GITR and 4-1BB or by blocking coinhibitory receptors, such as 
CTLA-4, PD-1. Right, list of other immune modulating receptors and developed 








Figure 2. A schematic overview of the clinical trials of monoclonal antibodies. 
Targets of monoclonal antibodies are depicted as molecular family and the current 








Glucocorticoid-induced TNF receptor family-related protein (GITR, also known as 
TNFRSF18, CD357) is a costimulatory molecule of the TNF receptor superfamily 
that has also emerged as a promising target for cancer immunotherapy6-8. 
Administration of GITR agonists has been well-documented to exert antitumor 
immune responses in diverse animal models of cancer9-14; this approach is currently 
under clinical investigation. Both CD4+ and CD8+ T cells have been shown to play 
pivotal roles in GITR agonist-induced tumor rejection9,10, while NK/NKT cells and B 
cells might also be involved in the antitumor activity10-12. Although GITR is 
constitutively expressed on Foxp3+ T cells, its role in GITR-mediated tumor 
regression is controversial at this stage11,13,14. Therefore, although accumulating 
evidence strongly suggests a beneficial effect of GITR agonists in generating 
antitumor immunity, the detailed mode of action remains poorly understood. 
CD4+ T cells orchestrate immune responses and help CD8+ T cells and B cells to 
induce cytotoxicity and antitumor Ab in the tumor microenvironment15. Among 
diverse TH subsets, TH1 cells are considered the most effective in rejecting tumors16-18. 
TH2 and Treg cells are generally thought to exert pro-tumorigenic activities by creating 
an immunosuppressive microenvironment in tumor-bearing hosts18-20, while the role 
of TH17 cells in tumors is still debatable21-23. In addition to TH1 cells, CD4+ T cells 
producing IL-9 (TH9) have recently been shown to trigger strong antitumor activity24,25. 
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Of note, TH9 cells display superior tumoricidal efficacy compared to TH1 cells in a 
mouse model of melanoma. In humans, fewer TH9 cells are present in metastatic 
melanoma lesions compared to PBMCs or skin from healthy donors28. These findings 
together suggest that promoting TH9 responses might be a promising 
immunotherapeutic approach for the treatment of cancer in humans. 
Polarization of naïve CD4+ T cells into the TH9 lineage requires the integration of 
multiple signals induced by the T cell receptor, IL-4 and TGF-β (Figure 3)26. In 
addition, several cytokines and transcription factors are necessary for optimal TH9 
differentiation27-34; however, the master transcription factor that dictates TH9 lineage 
commitment remains to be elucidated. Once differentiated, TH9 cells exert antitumor 
activity through targeting of mast cells24 and through the recruitment of DCs and 
subsequent induction of tumor-specific CD8+ CTL responses (Figure 4)25. In this 
study, we found that GITR ligation profoundly augments TH9 differentiation with 
concomitant inhibition of induced regulatory T cell (iTreg) integrity, of which might be 
expanded by tumors, and consequently promotes tumor-specific CTL responses in an 








Figure 3. Integration of multiple signals for TH9 cell development. 
Diverse transcription factors and signaling pathways contribute to induce IL-9 in 












Figure 4. The illustration of antitumor immunity induced by IL-9. 
IL-9 derived from TH9 cells can exert antitumor activity through mast cells or through 
directly acting on epithelial cells and subsequent recruitment and activation of DCs 







Materials and Methods 
 
Mice  
C57BL/6 and BALB/c mice were purchased from Charles River Laboratories and 
DO11.10, OT-II and CD4Cre mice were from the Jackson Laboratory. Il4-/- and Il4ra-/- 
mice were kindly provided by Doo Hyun Chung (Seoul National University College 
of Medicine) and Yoon-Keun Kim (Ewha Institute of Convergence Medicine), 
respectively. GITR-/-, Foxp3GFP and Traf6fl/fl mice were previously described35-37. Mice 
were bred and maintained in the specific pathogen-free animal facility at Seoul 
National University. All animal experiments were approved by the Institutional 
Animal Care and Use Committee at Seoul National University (SNU-110429-1). 
 
Tumor models and cell preparation  
CT26 cells (3×105 per mouse; ATCC) and B16F10-Ova cells (106 per mouse; a kind 
gift from Kenneth Rock, University of Massachusetts) were subcutaneously injected 
into the left flank of BALB/c, Il4ra-/- mice and C57BL/6 mice, respectively. Some 
mice received intraperitoneal injections of 600 µg anti-GITR mAb (DTA-1; kindly 
provided by S. Sakaguchi, Osaka University) on day 5 and/or 200 µg anti-IL-9 mAb 
(MM9C1; generously provided by J. v. Snick, Ludwig Institute) on day 5, 7, 9, 12 and 
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15 following tumor inoculation. For CD4+ T cell depletion, mice were 
intraperitoneally injected with 200 µg anti-CD4 mAb (GK1.5; ATCC) on day 3 and 4 
following tumor inoculation. Rat IgG or mouse IgG (Sigma-Aldrich) was used as 
control. Tumor volume (mm3) was calculated as 0.5236 × length × width × height. For 
cellular analyses, 2×105 or 106 total cells, sorted CD4+ T cells and non-CD4 cells from 
tumor draining lymph nodes (TdLNs) at the indicated time points were stimulated 
with anti-CD3 plus anti-CD28 or IL-2 for 48 h for protein detection and with anti-
CD3 for 4 h for mRNA analyses. Tumor-infiltrating lymphocytes were prepared by 
enzyme digestion with 1 mg ml-1 collagenase (Roche), 0.5 mg ml-1 DNase I and 25 µg 
ml-1 hyaluronidase (Sigma-Aldrich) at 37℃ for 30 min, followed by Percoll (GE 
Healthcare) gradient purification. 
For adoptive transfer studies, in vitro-generated Ova-specific TH2, TH9 or anti-GITR-
treated TH9 cells (1.5×106 per mouse) and CFSE (5 µM; Invitrogen)-labeled, Ova-
specific iTreg cells (2×106 per mouse) were transferred intravenously into C57BL/6 
mice inoculated with B16F10-Ova on the same day and mice bearing 5-day 
established B16F10-Ova, respectively. Anti-IL-9 mAb was administered every 3 days 
from 1 day before TH9 cell transfer, and tumor growth was monitored. Anti-GITR 
mAb was administered 1 day after iTreg cell transfer and donor cells were analyzed 5 
days after Ab treatment. 
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Cytotoxic T lymphocyte assay  
Pooled splenocytes and TdLN cells from tumor-bearing mice were stimulated with an 
MHC I-restricted tumor epitope (AH1, gp70423-431 (SPSYVYHQF); Anygen) for 5d. 
After 5d stimulation, identical numbers of live cells were cocultured with 51Cr-labeled 
CT26 tumor cells for 4 h. CTL activity was calculated by 51Cr release in culture 
supernatants through specific lyses of CT26 target cells, measured by a Wallac 1470 
Wizard automatic γ-counter (PerkinElmer). To characterize CD8+ CTLs, 5-day 
stimulated effector cells were restimulated with an AH1 (1 µM) plus Brefeldin A (1 
µg ml-1, GolgiPlug; BD Biosciences) for 4 h and analyzed by flow cytometry. An 
APC-conjugated Ab to CD107a (1D4B; BioLegend) was added during cell 
restimulation. 
 
In vitro TH cell differentiation  
Naïve CD4+CD44loCD62LhiCD25-(Foxp3-) T cells were purified by FACSAria III 
(BD Bioscience) from enriched CD4+ cells via positive selection with CD4 MACS 
bead (Miltenyi) according to the manufacturer’s instructions. Sorted naïve CD4+ T 
cells were stimulated for 3 or 4 days with plate-bound anti-CD3 (2 µg ml-1, 145-2C11; 
BioLegend) and immobilized anti-CD28 (1 µg ml-1, 37.51; BioLegend) or irradiated 
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T cell-depleted splenocytes (1:4 ratio), supplemented with mIL-2 (10 ng ml-1; 
eBioscience, not for TH17). Ova-specific CD4+ T cells were stimulated for 3d with 
irradiated T cell-depleted splenocytes plus a cognate OVA323-339 peptide (Anygen). To 
polarize T cells to a specific TH subset, the following cytokines were added to 
cultures: TH1 (4 ng ml-1 IL-12), TH2 (10 ng ml-1 IL-4), TH17 (5 ng ml-1 TGF-β plus 20 
ng ml-1 IL-6), iTreg (5 ng ml-1 TGF-β) and TH9 (5 ng ml-1 TGF-β plus 10 ng ml-1 IL-4). 
All cytokines were from eBioscience except TGF-β from PeproTech. Adoptively 
transferred T cells were generated from naïve OT-II cells stimulated with anti-CD3 
and anti-CD28. To generate adoptively transferred iTreg cells, anti-IFN-γ (10 µg ml-1, 
R4-6A2; ATCC) and anti-IL-4 (10 µg ml-1, 11B11; ATCC) were additionally 
supplemented. 
 
Human samples. Human peripheral blood was obtained from healthy volunteers and 
informed consent was granted from all donors. Peripheral blood mononuclear cells 
(PBMCs) were prepared by Ficoll-Hystopaque (Sigma-Aldrich) density gradient 
centrifugation and further isolated for naïve CD3+CD4+CD45RA+CD45RO-CD25- T 
cells from enriched CD4+ cells by flow cytometry. Sorted naïve CD4+ T cells were 
stimulated with plate-bound anti-CD3 (10 µg ml-1, OKT3; BioLegend) and soluble 
anti-CD28 (2 µg ml-1, CD28.2; BioLegend) in the presence of pre-coated mouse 
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IgG1 antibody or anti-hGITR antibody (20 or 50 µg ml-1) 38 under TH9 condition. The 
collection of human samples and all human experiments were approved by the ethical 
committee of Seoul National University (IRB No. 1406/ 001-024). 
 
Antibodies and flow cytometry. FITC-conjugated Abs to mouse CD3ε (145-2C11), 
Foxp3 (FJK-16s; eBioscience) and human CD45RA (HI100), PE-conjugated Abs to 
mouse CD8α (53-6.7), Vα2 (B20.1), GITR (DTA-1), IFN-γ (XMG1.2), IL-4 (11B11), 
IL-13 (eBio13A; eBioscience), IL-17A (TC11-18H10.1) and human IL-9 (MH9A4), 
PerCP-Cy5.5-conjugated Abs to mouse CD3ε (145-2C11), CD62L (MEL-14), 
PE/Cy7-conjugated Abs to mouse CD4 (RM4-5; eBioscience), CD44 (IM7), CD45.1 
(A20), TNF-α (MP6-XT22), IFN-γ (XMG1.2) and human CD4 (RPA-T4), CD45RO 
(UCHL1), APC-conjugated Abs to mouse CD4 (RM4-5), CD25 (PC61), IL-9 
(RM9A4) and human CD25 (BC96), Foxp3(236A/E7; eBioscience), AlexaFluor647-
conjugated Ab to mouse Granzyme B (GB11), APC/Cy7-conjugated Ab to mouse 
CD4 (RM4-5) and human CD3 (OKT3) and Pacific blue-conjugated Ab to human 
CD4 (RPA-T4) were used. Abs were all from BioLegend unless otherwise indicated. 
For intracellular cytokine staining of in vitro-generated T cells, cells were restimulated 
with phorbol 12-myristate 13-acetate (50 ng ml-1; Sigma-Aldrich) and ionomycin (500 
ng ml-1; Sigma-Aldrich) plus Brefeldin A for 4 h, followed by fixation and 
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permeabilization using Cytofix/Cytoperm kit (BD Biosciences). For Foxp3 staining, 
cells were permeabilized with a Foxp3 staining kit (eBioscience) according to the 
manufacturer’s instructions. Samples were acquired with FACSCalibur or FACSAria 
III (BD Bioscience) and data were analyzed with FlowJo software (Tree Star). 
 
Quantitative real-time PCR assay. Total RNA was extracted with TRIzol reagent 
(Invitrogen) and was reverse-transcribed using SuperScript reverse transcriptase and 
oligo(dT) primers (Invitrogen). Synthesized cDNA was quantified with a SYBR 
Green real-time PCR kit (Takara) and LightCycler optical system (Roche). The 
expression levels of target genes were normalized to the amount of Hprt expression. 
Primer pairs used for analyses were as follows: murine Il4 sense (ATCCACGGAT-
GCGACAAAAA), murine Il4 antisense (GTGGTGTTCTTCGTTGCTGTGA), 
product size 125 bp; murine Il13 sense (GGATATTGCATGGCCTCTGTAAC), 
murine Il13 antisense (GTGGCGAAACAGTTGCTTTG), product size 125 bp; 
murine Il10 sense (GGGTTGCCAAGCCTTATCG), murine Il10 antisense (CACCC-
AGGGAATTCAAATGCT), product size 107 bp; murine Il9 sense (AACGTGACC-
AGCTGCTTGTGT), murine Il9 antisense (CTTGATTTCTGTGTGGCATTGG), 
product size 104 bp; murine Il9r sense (TGAAATCAAACACAAATGCACCTT), 
murine Il9r antisense (GATGCAGCGGTGAAGTGTGA), product size 112 bp; 
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human Il9 sense (TCCTGGACATCAACTTCCTCATC), human Il9 antisense (GGA-
ATGCCCAAACAGAGACAAC), product size 100 bp; murine Foxp3 sense (GGA-
TGAGCTGACTGCAATTCTG), murine Foxp3 antisense (GTACCTAGCTGCCCT-
GCATGAG), product size 120 bp; murine PU.1 sense (GCCTCAGTCACCAGGTT-
TCC), murine PU.1 antisense (CTCTCACCCTCCTCCTCATCTG), product size 100 
bp; murine Irf4 sense (GCCTTGGCGCTCTCAGACT), murine Irf4 antisense (CAT-
AGGTGTGTCCGTGGGAGAT), product size 118 bp; murine Gata3 sense (CCTGC-
GGACTCTACCATAAAA), murine Gata3 antisense (GTGGTGGTGGTCTGACAG-
TTC), product size 118 bp; murine Batf sense (GCCGACAGAGACAGACACA-
GAA), murine Batf antisense (TCGGTGAGCTGTTTGATCTCTTT), product size 
103 bp; murine Traf1 sense (ATGCCAGCAGCTTCTGAATGTT), murine Traf1 
antisense (GCCCTGACCTCGAGAGAATGT), product size 138 bp; murine Traf2 
sense (TCTGTTGCAGTGGCCTTTTAATC), murine Traf2 antisense (TGGCGATG-
TTCATGTCACTGA), product size 140 bp; murine Traf3 sense (TGCTGGTGCAC-
CTAAAAAATGA), murine Traf3 antisense (CGGTATTTACAGGCCTTTTCCA), 
product size 121 bp; murine Traf4 sense (CACTGAGACCTTCCACCCTGAT), 
murine Traf4 antisense (CCGCACGTAGTTCCGCTTT), product size 145 bp; murine 
Traf5 sense (GAAAGAGCACCTGAGCGCATAC), murine Traf5 antisense (GTA-
CGCAGGACACGAGTTTTCC), product size 115 bp; murine Traf6 sense (GGAAT-
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CACTTGGCACGACACTT), murine Traf6 antisense (CATCGCACGGACGCAAA), 
product size 102 bp; murine Traf7 sense (TGATGGGACTGGCACATACAAA), 
murine Traf7 antisense (GAACGGACAGAGATGGCTGAGT), product size 141 bp; 
murine Hprt sense (AAGACTTGCTCGAGATGTCATGAA), murine Hprt antisense 
(ATCCAGCAGGTCAGCAAAGAA), product size 100 bp; human Hprt1 sense (TT-
GCTCGAGATGTGATGAAGGA), human Hprt1 antisense (ATGTAATCCAGCAG-
GTCAGCAAA), product size 100 bp. 
 
In vitro T cell suppression assay. CFSE-labeled CD4+CD25- T cells from CD45.1+ 
congenic mice were cultured with irradiated T cell-depleted splenocytes (1:4 ratio) 
plus soluble anti-CD3 (1 µg ml-1). Foxp3GFP mice were challenged subcutaneously 
with B16F10-Ova melanoma 5 days before treatment with control IgG or anti-GITR 
mAb. CD4+Foxp3+ T cells (CD45.2+) sorted from TdLNs 8 days after Ab treatment 
were added to cultures at different ratios. Three days later, the suppressive function of 
Treg cells was analyzed on the basis of CFSE-dilution gated on CD45.1+. 
 
Immunoblot analysis. Fractionation of cytosolic and nuclear protein extracts was 
performed with a Subcellular Proteome Extraction Kit (Calbiochem) according to the 
manufacturer’s instructions. Protein extracts were separated by SDS-PAGE and 
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transferred to Immobilon membranes (Millipore). Membranes were stained with 
specific Abs to analyze the expression of receptor and signaling subunits. 
 
Statistical analysis. An unpaired two-tailed Student’s t test was used for statistical 
analyses. Results with a P value of < 0.05 were considered statistically significant. 

















IL-4R signaling is required for GITR agonist-induced tumor regression 
As a first step to investigate the mechanism by which GITR signaling mediates 
antitumor activity, I employed a well-established syngeneic mouse model of cancer. 
Groups of BALB/c mice were subcutaneously injected with CT26 tumor cells in the 
flank 5 days before receiving an additional injection with agonistic anti-GITR (DTA-
1) or control IgG. Consistent with previous studies, anti-GITR significantly 
suppressed tumor growth, which was almost completely reversed by CD4 depletion 
(Figure 5a). Because GITR costimulation has been reported to enhance TH2 
responses39-41, I determined whether GITR-induced antitumor activity was associated 
with TH2 immunity. Indeed, I observed that the levels of Il4, Il13 and Il10 transcripts 
in TdLNs were all significantly increased by anti-GITR (Figure 5b). More 
importantly, anti-GITR failed to inhibit tumor growth when Il4ra-/- mice were used as 
recipients (Figures 5c and 5d). These data demonstrate indispensable roles of CD4+ T 








Figure 5. IL-4R signaling is essential for anti-GITR-induced tumor inhibition.  
(a) Tumor size in mice subcutaneously injected with CT26 tumor cells. Some mice 
additionally received anti-CD4 and/or anti-GITR mAb (DTA-1). Total rat IgG was 
injected as a control. (b) Expression of Il4, Il13 and Il10 transcripts in TdLNs of 10-
day established CT26 tumor-bearing mice treated with control IgG or DTA-1 5d 
before. Inguinal and axillary LNs of naïve BALB/c mice were analyzed for the 
“Tumor-free”. Data were normalized to the expression of Hprt. (c,d) Tumor growth 
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curves of individual mice (c) and mean ± s.e.m. values of tumor volume (d) in wild-
type (WT) littermates and Il4ra-/- mice injected with CT26 tumor cells and control IgG 
or DTA-1 are depicted (n = 5 or 6). * P < 0.05, ** P < 0.01, *** P < 0.001 by 

















IL-9 mediates antitumor activity induced by anti-GITR 
The observed essential role of CD4+ T cells and IL-4Ra in GITR-induced antitumor 
activity prompted us to examine the involvement of TH2 and TH9 cells, because the 
differentiation of these helper T cells requires IL-4 signaling42-44. When in vitro-
generated Ova-specific TH2 and TH9 cells (Figure 6a) were transferred into Ova-
expressing B16F10 melanoma-bearing mice, TH9 recipients showed significantly 
delayed tumor growth compared with TH2 recipients, although TH2 recipients also 
showed slightly delayed tumor growth compared with control mice that did not 
receive any T cells (Figure 6b), indicating that TH9 cells were superior to TH2 cells in 
mediating antitumor activity in this experimental setting. Hence, I checked the levels 
of IL-9 and found that Il9 transcript and IL-9 protein in TdLNs were significantly 
increased by administration of anti-GITR (Figures 7a-c) and were almost completely 
abolished in Il4ra-/- mice (Figure 7a). Kinetic analysis of Il9 transcript expression 
revealed that anti-GITR enhanced IL-9 expression, starting from day 2 and reaching a 
peak around day 5 after Ab treatment, followed by gradual down-regulation thereafter 
(Figures 7b and 7c). To further determine the source of IL-9, I sorted CD4+ T cells 
and non-CD4 populations from TdLNs before stimulating them with anti-CD3 plus 
anti-CD28 or with IL-2. As depicted in Figure 7c, I found that the major source of IL-
9 was CD4+ T cells and that anti-GITR profoundly increased IL-9 production by 
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CD4+ T cells. 
Notably, recent studies have proposed an anti-tumorigenic role of IL-924,25. Thus, I 
sought to determine whether IL-9 is required for the observed tumor regression 
induced by anti-GITR by employing a neutralizing anti-IL-9 Ab. Importantly, I found 
that neutralization of IL-9 significantly reversed anti-GITR-mediated tumor regression 
(Figures 7d and 7e). In addition, when in vitro-generated Ova-specific TH9 cells were 
transferred into mice bearing B16F10-Ova, anti-GITR further improved the antitumor 
activity of TH9 cells via an IL-9-dependent mechanism (Figure 7f). Collectively, these 
results demonstrate that anti-GITR exerted antitumor activity by triggering IL-9 














Figure 6. TH9 cells are superior to TH2 cells in rejecting tumors.  
(a) Flow cytometry of in vitro-generated TH2 and TH9 cells from naïve OT-II mice. (b) 
Tumor size in C57BL/6 mice with s.c. inoculation of B16F10-Ova cells and i.v. 
transfer of in vitro-generated TH2 or TH9 cells on the same day (n = 5). * P < 0.05, *** 












Figure 7. Anti-GITR-mediated tumor regression requires IL-9. (a) Il9 mRNA 
expression in TdLNs of CT26 tumor-bearing WT and Il4ra-/- mice injected with 
control IgG or DTA-1 5d before. Naïve BALB/c mice were used for the “Tumor-free”. 
(b) Kinetic analysis of Il9 transcript expression in TdLNs of CT26 tumor-bearing 
hosts treated with control IgG or DTA-1 5d after tumor inoculation. (c) IL-9 
concentration in supernatants from total cells, CD4+ T cells and non-CD4 cells 
isolated at the indicated time points. (d,e) Tumor growth curves of individual mice (d) 
and mean ± s.e.m. values of tumor volume (e) in BALB/c mice with s.c. injection of 
CT26 tumor cells and i.p. administration of DTA-1 (arrow) and/or anti-IL-9 Abs at 
the indicated time points (n = 7 or 8). Total rat IgG and mouse IgG were used as 
controls. (f) Tumor size measured over time after s.c. inoculation of B16F10-Ova cells 
and i.v. injection of in vitro-generated TH9 or DTA-1-treated TH9 cells on the same 
day. IL-9 neutralizing Ab was administered i.p. every 3 days from 1 day before cell 
transfer. * P < 0.05, ** P < 0.01, *** P < 0.001 by Student’s t test. Data represent two 





Anti-GITR drives TH9 cell differentiation in a T cell-intrinsic manner 
Since IL-9 was found to be crucial in antitumor activity induced by anti-GITR and it 
was mainly produced by CD4+ T cells, I hypothesized that GITR signaling potentiates 
IL-9 production by CD4+ T cells. The expression level of GITR was low in naïve TH 
cells and was similar among differentiating TH1, TH2, TH9, iTreg cells and natural Treg 
(nTreg) cells (Figure 8a). When anti-GITR was added during in vitro T cell stimulation 
with plate-bound anti-CD3 and anti-CD28 under TH1, TH17 and Treg conditions, it 
moderately inhibited the expression of IFN-γ, IL-17 and Foxp3, respectively (Figure 
9a). In sharp contrast, anti-GITR significantly increased IL-13 production under TH2 
condition. Importantly, a small but evident subpopulation of IL-13+ cells co-expressed 
IL-9 in this condition (Figure 8b). Under TH9 condition, the addition of anti-GITR 
significantly increased the frequencies of IL-9+IL-13+ and IL-9+IL-13- T cells (Figure 
8b). Accordingly, IL-9 production and Il9 transcript expression by CD4+ T cells 
stimulated under TH2- or TH9-skewing condition were profoundly increased by anti-
GITR (Figure 8c). I observed a similar increase of IL-9 expression by anti-GITR 
when Ova-specific CD4+ T cells were stimulated with cognate peptide and irradiated 
antigen-presenting cells (APCs) (Figures 9b and 9c). As depicted in Figure 8d, 
GITR-deficient CD4+ T cells failed to increase IL-9 production in response to anti-
GITR, regardless of whether they were stimulated with APC plus anti-CD3 or with 
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anti-CD3 plus anti-CD28. Similarly, the addition of agonistic anti-human GITR 
significantly increased IL-9 expression in human CD4+ T cells stimulated under TH9-
skewing condition in a dose dependent manner (Figures 8e-g). These results together 
demonstrate that GITR costimulation preferentially promotes IL-9 production by 


















Figure 8. GITR costimulation enhances murine and human TH9 differentiation 
in vitro. (a) Expression of GITR in freshly isolated naïve CD4+ T cells, natural Treg 
cells and differentiating TH subsets at 24 h. (b) Left, intracellular staining of IL-9 and 
IL-13 in naïve CD4+ T cells from Foxp3GFP mice stimulated for 3d with anti-CD3 plus 
anti-CD28 and isotype control Ab or DTA-1 under the indicated TH polarizing 
conditions. Right, the percentages of IL-9-producing T cells gated on CD4+ cells, 
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along with the proportions of IL-9+IL-13+ and IL-9+IL-13- T cells. (c) Left, IL-9 
production by CD4+ T cells cultured as in b, followed by restimulation with anti-CD3 
for 24 h. Right, Il9 mRNA expression in CD4+ T cells cultured as in b at 48 h. (d) IL-
9 production by naïve CD4+ T cells from WT or GITR-/- mice stimulated under TH9 
condition with APC- or APC-free systems. (e) Left, intracellular IL-9 and IL-10 in 
human naïve CD4+ T cells cultured for 4d under TH9 condition. Right, the percentages 
of IL-9+ cells gated on CD4+ cells. A dot means an individual PBMC donor. (f) Il9 
mRNA expression in human CD4+ T cells cultured as in e at 48 h. (g) The percentages 
of IL-9+ cells gated on CD4+ cells cultured with gradual concentrations of isotype 
control Ab or anti-hGITR. ** P < 0.01, *** P < 0.001 by Student’s t test. n.s. non-












Figure 9. Effects of GITR costimulation on the differentiation of TH subsets.  
(a) Expression of IFN-γ, IL-17A and Foxp3 in naïve CD4+ T cells stimulated for 3d 
under TH1-, TH17- and iTreg-polarizing conditions in the presence of isotype control 
Ab or DTA-1. (b,c) IL-9 production by naïve CD4+ T cells stimulated for 3d under the 
indicated TH conditions plus isotype control Ab or DTA-1, measured by flow 
cytometry (b) and by ELISA (c) in accumulated supernatants of the culture. * P < 





Anti-GITR inhibits the generation and maintenance of induced Treg cells 
Foxp3+ Treg cells are one of major obstacles for cancer immunotherapies, and the 
tumor microenvironment is known to promote the generation of iTreg cells20. Both 
natural and induced Treg cells express GITR on their surface (Figure 8a), and thus I 
analyzed the impact of anti-GITR on Treg cells in the tumor microenvironment. 
Although anti-GITR moderately increased the frequencies of Foxp3+ cells among 
CD4+ T cells in TdLNs, it substantially reduced those among tumor-infiltrating CD4+ 
T cells (Figure 10a). Thus, I next tested whether GITR stimulation impacts the 
stability and function of nTreg cells. Stimulation of nTreg cells by anti-GITR alone 
showed little effect on the expression of Foxp3 and IL-9; however, when they were 
stimulated in the presence of IL-4, anti-GITR slightly but significantly induced IL-9-
producing Foxp3+ Treg cells and Foxp3-IL-9+ T cells, albeit in small populations 
(Figures 11a and 11b). In vitro-generated iTreg cells were more flexible than nTreg 
cells (Figure 12). The suppressive activity of Treg cells remained comparable 









Figure 10. GITR triggering regulates de novo generation and stability of iTreg 
cells. (a) The percentages of Foxp3+ cells gated on CD4+ cells from TdLNs and 
tumors of Foxp3GFP mice 8d after i.p. injection of control IgG or DTA-1 that was 5d 
after s.c. inoculation of B16F10-Ova. (b) Left, expression of Foxp3 and IL-9 in naïve 
CD4+ T cells differentiated under iTreg condition in the presence of isotype control Ab 
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or DTA-1. The percentages of Foxp3+ cells (Middle) and IL-9+ cells (Right) gated on 
CD4+ cells at the end of cultures. (c) Expression of Foxp3 and Il9 transcripts in CD4+ 
T cells cultured as in b at 48 h. (d) Left, flow cytometry of Foxp3 in in vitro-generated 
CFSE+Vα2+ iTreg cells from naïve OT-II mice that were i.v. transferred into C57BL/6 
mice bearing 5-day established B16F10-Ova. Foxp3 expression in donor cells from 
TdLNs was analyzed 6d after transfer. Right, the percentages of Foxp3+ cells in 
CFSE+ Vα2+ donor cells are depicted. A dot represents an individual mouse. Bars 
indicate mean values. ** P < 0.01, *** P < 0.001 by Student’s t test. Data represent 















Figure 11. Effects of GITR costimulation on the integrity and function of nTreg 
cells. (a) Left, sorted CD4+Foxp3+ natural Treg (nTreg) cells (purity>99%) from 
Foxp3GFP reporter mice were activated for 4d with anti-CD3 plus anti-CD28 and 
isotype control Ab or DTA-1, with or without TGF-β and/or IL-4 and were analyzed 
for IL-9 and Foxp3 (GFP) expression by flow cytometry. Right, the frequencies of IL-
9+ cells in nTreg cell cultures are depicted. (b) IL-9 production by nTreg cells stimulated 
as in a. (c) Suppressive function of Treg cells isolated from naïve Foxp3GFP mice or 
mice bearing B16F10-Ova with in vivo treatment of control IgG or DTA-1. ** P < 





Figure 12. Flexible reprogramming of iTreg cells to IL-13- or IL-9-producing T 
cells. Sorted CD4+Foxp3-GFP+ iTreg cells from naïve CD4+ T cells (originated from 
Foxp3-GFP reporter mice) cultured with TGF-β and IL-2 for 3d were stimulated once 
more with anti-CD3 plus anti-CD28 in the presence of indicated cytokines and DTA-1. 
After 4 days culture, the expression of Foxp3 (GFP) and IL-13 or IL-9 was analyzed 





Notably, the addition of anti-GITR significantly inhibited the differentiation of iTreg 
cells in response to TGF-β and triggered them to become IL-9-producing Foxp3- T 
cells even in the absence of exogenous IL-4 (Figures 10b and 10c). Also, anti-GITR 
inhibited the generation of human iTreg cells in vitro (Figure 13). To further address 
the role of GITR on the maintenance of iTreg cells in the context of tumor, I generated 
iTreg cells from OT-II cells, and adoptively transferred them into mice bearing 
B16F10-Ova tumor. As illustrated in Figure 10d, anti-GITR significantly down-
regulated the frequency of tumor-specific Foxp3+ T cells among donor cells. Together 
these results suggest that GITR signaling hampers the generation and maintenance of 
Foxp3+ iTreg cells, and instead induces IL-9 production from T cells that were 
previously committed to the IL-9-Foxp3+ lineage. 
To determine the underlying mechanism of GITR-mediated IL-9 induction by CD4+ T 
cells, I examined the involvement of TGF-β, an essential cytokine for TH9 conversion. 
I checked whether anti-GITR altered the expression of TGF-β or TGF-β receptor by 
CD4+ T cells, but none of them were changed (Figure 14a). Published report has 
shown that Activin A, a TGF-β family member, can induce TH9 differentiation. I 
detected the increased expression of Activin βA by anti-GITR (Figure 14b), but 
neutralization of Activin A slightly inhibited the IL-9 increase only in the absence of 





Figure 13. Anti-GITR inhibits the differentiation of human iTreg cells.  
Sorted CD3+CD4+CD45RA+CD45RO-CD25- T cells from human PBMCs were 
cultured with TGF-β in the presence of allogeneic monocyte-derived DCs and 
immobilized anti-CD3 plus isotype control Ab or anti-hGITR. After 4 days, 











Figure 14. TGF-β family are not responsible for the enhancement of TH9 
differentiation by anti-GITR. (a) Expression of Tgfb1, Tgfbr1 and Tgfbr2 transcripts 
in naïve CD4+ T cells cultured with TGF-β, IL-4 and isotype control Ab or DTA-1 for 
48h. (b) Expression of Activin βA transcript in naïve CD4+ T cells cultured as in a. (c) 
Intracellular staining of IL-9 in naïve CD4+ T cells cultured as in a with or without 





Next, I checked IL-4 since autocrine IL-4 has been suggested to be crucial for IL-9 
production by T cells45. Indeed, anti-GITR remarkably potentiated IL-4 production by 
CD4+ T cells (Figures 15a and 15b). If anti-GITR increased IL-9 production through 
this autocrine IL-4, the addition of excessive IL-4 would extinguish the IL-9-inducing 
capacity of anti-GITR. However, anti-GITR enhanced IL-9 production, even in an IL-
4-abundant condition (100 ng/ml IL-4), suggesting that increased IL-4 might not 
account for GITR-mediated IL-9 induction by T cells (Figure 15c). Consistent with 
this notion, Il4-/- T cells produced comparable amounts of IL-9 to wild-type T cells in 
response to TGF-β and/or IL-4 in combination with anti-GITR (Figures 15d and 15e). 
Furthermore, anti-GITR triggered the expression of IL-9 in response to TGF-β even in 
Il4ra-/- T cells, although it was less extent than wild-type T cells (Figure 16). Together, 
our data indicate that although anti-GITR induced IL-4 production by T cells, it could 









Figure 15. Autocrine IL-4 is dispensable for GITR-mediated TH9 differentiation. 
(a) Il4 mRNA expression in naïve CD4+ T cells stimulated for 48 h with anti-CD3 
plus anti-CD28 and isotype control Ab or DTA-1, with or without TGF-β and/or IL-4. 
(b) IL-4 in accumulated supernatants of CD4+ T cells cultured as in a for 3d. (c) The 
frequencies of IL-9+ cells in CD4+ T cells activated as in a plus TGF-β and different 
concentrations of IL-4 (0-100 ng/ml). (d,e) IL-9 production in naïve CD4+ T cells 
from WT and Il4-/- mice stimulated  for 3d as in a, measured by flow cytometry (d) 
and by ELISA (e). n.s. non-significant, * P < 0.05, ** P < 0.01, *** P < 0.001 by 





Figure 16. IL-4 signaling is not necessary for GITR-induced TH9 differentiation, 
but required for optimal IL-9 production. (a,b) IL-9 production by naïve CD4+ T 
cells from wild-type littermates and Il4ra-/- mice stimulated for 3d with anti-CD3 plus 
anti-CD28 and isotype control Ab or DTA-1, with or without TGF-β and/or IL-4, 
measured by flow cytometry (a) and by ELISA (b) in accumulated supernatants of the 
culture. N.D. Not done, * P < 0.05, ** P < 0.01, *** P < 0.001 by Student’s t test. 




TRAF6-NF-κB pathway is required for GITR-mediated TH9 differentiation 
To further dissect the molecular mechanisms directing TH9 differentiation by GITR 
costimulation, I analyzed multiple transcription factors that are known to be crucial 
for TH9 cell lineage commitment29-32. Kinetic analyses showed that the levels of PU.1, 
Irf4, Gata3 and Batf were either unchanged or slightly upregulated by anti-GITR 
(Figure 17). The NF-κB pathway has been reported to be essential for IL-9 
expression46,47, particularly in response to OX40 signaling34. I found that stimulation 
of naïve CD4+ T cells with anti-CD3 plus anti-CD28 induced the activation of NF-κB 
signaling and that anti-GITR both accelerated and prolonged the activation of the 
canonical and noncanonical NF-κB signal transduction pathways (Figure 18a). When 
activated CD4+ T cells were pretreated with BAY 11-7082, a chemical inhibitor of the 
NF-κB pathway, the IL-9-inducing capacity of anti-GITR was reduced in a dose-
dependent manner without altering cell survival (Figures 18b and 18c), suggesting 
that GITR signaling might mediate TH9 differentiation through enhancing NF-κB 









Figure 17. Kinetic analyses of the TH9-related gene expression following anti-
GITR treatment. Expression of the indicated genes in naïve CD4+ T cells activated 
with anti-CD3 and anti-CD28 in the presence of isotype control Ab or DTA-1, with or 















Figure 18. TRAF6-NF-κB pathway is associated with GITR-mediated TH9 
differentiation. (a) Immunoblots of the canonical and noncanonical NF-κB signaling 
subunits in the cytosolic and nucleic fractions of naïve CD4+ T cells freshly isolated or 
anti-CD3 plus anti-CD28-stimulated in the presence of isotype control Ab or DTA-1. 
(b) Blot images of the NF-κB signaling subunits in the nucleus of naïve CD4+ T cells 
preactivated with anti-CD3 and anti-CD28 for 24 h, treated with the vehicle or 
indicated concentrations of BAY 11-7082 for 30 min and stimulated with anti-CD3 
plus anti-CD28 and isotype control Ab or DTA-1 for 6 h. (c) Naïve CD4+ T cells were 
cultured as in b under TH9-polarizing condition and IL-9 production was measured 2d 
after the addition of isotype control Ab or DTA-1. (d) IL-9 production by naïve CD4+ 
T cells from Traf6fl/fl (WT) and Traf6fl/flCd4Cre mice activated with irradiated T cell-
depleted splenocytes plus anti-CD3 and isotype control Ab or DTA-1 under TH9-








To further investigate this molecular requirement, I determined the involvement of the 
TRAF family, as they are well-known adaptor molecules that activate the NF-κB 
pathway. In particular, TRAF6 has recently been shown to mediate TH9 
differentiation34. Anti-GITR upregulated the expression of Traf6 transcript in T cells 
(Figure 19). Moreover, when TRAF6-deficient CD4+ T cells were stimulated under 
TH9-skewing condition, anti-GITR failed to increase IL-9 production by T cells 
(Figure 18d). These results strongly suggest that the TRAF6-NF-κB axis is a crucial 















Figure 19. Traf6 expression is upregulated by anti-GITR.  
Expression of TRAF family transcripts in naïve CD4+ T cells stimulated for 48h with 
irradiated T cell-depleted total splenocytes and anti-CD3 in the presence of isotype 









IL-9 triggered by anti-GITR potentiates tumor-specific CTL responses 
Both CT26 and B16F10-Ova tumor cells were found not to express the IL-9 receptor 
(Figures 20a and 20b), indicating that IL-9 exerts antitumor activity through the 
activation of effector cells rather than acting directly on tumor cells. Given that GITR 
agonists are known to induce tumor-specific CTL responses9-11, I examined whether 
IL-9 induced by anti-GITR mediates tumor-specific CTL responses. Indeed, anti-
GITR-treated mice showed a profound target cell killing activity compared with 
control IgG-treated mice. Notably, administration of anti-IL-9 suppressed CTL 
responses induced by anti-GITR. It is noteworthy that anti-IL-9 did not completely 
reverse the CTL-inducing capacity of anti-GITR, suggesting that there might be an 
IL-9-independent pathway in anti-GITR-triggered CTL responses (Figure 21a). 
Similarly, the percentages of live CD8+ T cells after ex vivo restimulation with a MHC 
I-restricted tumor epitope were increased in anti-GITR-treated mice, which was 
significantly reduced by anti-IL-9 (Figure 21b). Furthermore, while the expression of 
effector cytokines such as Granzyme B, IFN-γ and TNF-α and a cytolytic marker 
CD107a in CD8+ CTLs were remarkably increased by anti-GITR, co-administration 
of anti-IL-9 significantly reduced the expression of these molecules by CD8+ T cells, 
suggesting that IL-9 plays a pivotal role for activation and functional maturation of 
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cytotoxic T cells in this experimental setting (Figures 21c and 21d). Collectively, 
these results demonstrate a crucial role of IL-9 in mediating tumor-specific CTL 





Figure 20. IL-9 receptor expression on tumor and immune cells.  
(a) Expression of the Il9r transcript in tumor cell lines and immune cells freshly 
isolated or stimulated with anti-CD3 and anti-CD28 for T cells and with LPS (1 µg 
ml-1) for DCs. (b) Immunoblot analysis of the expression of IL-9 receptor in cells 







Figure 21. IL-9 induced by anti-GITR facilitates antitumor CTL responses.  
(a) Analysis of the cytotoxicity of total splenocytes and TdLN cells (day 14) from 
CT26 tumor-bearing mice treated as described in Materials and Methods, followed 
by stimulation with a gp70 epitope for 5d. 51Cr-labeled CT26 tumor cells were used as 
target cells. (b) The percentages of live CD8+ T cells obtained 5d after stimulation 
with a gp70 epitope. (c) Expression of Granzyme B, IFN-γ, TNF-α and CD107a in 
CD8+ T cells prepared as in a. (d) The percentages of Granzyme B, IFN-γ, TNF-α and 
CD107a-positive cells are depicted. A dot represents an individual mouse. Bars 
indicate mean values. * P < 0.05, ** P < 0.01, *** P < 0.001 by Student’s t test. Data 
represent two independent experiments. 
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GITR-induced IL-9 activates tumor-infiltrating DCs in vivo 
To further investigate whether IL-9 directly induced CD8+ T cell differentiation, I 
isolated Ova-specific CD8+ T cells from OT-I mice and cocultured with CFSE-labeled 
B16F10-Ova tumor cells with or without recombinant IL-9. In the presence of Ova-
specific CD8+ T cells, CFSE+ 7-AAD+ apoptotic tumor cells were increased; however, 
IL-9 did not affect the cytotoxicity of CD8+ T cells (Figure 22). This result indicates 
that other intermediaries mediate the differentiation of tumor-specific CD8+ CTLs in 
response to IL-9. 
Recent reports have demonstrated that mast cells and DCs mediate TH9 or IL-9-
induced tumor rejection (Purwar et al., 2012; Lu et al., 2012). Thus, I first depleted 
mast cells by anti-c-kit mAb (ACK2) in a CT26 tumor model (Figures 23a and 23b). 
Although about 75% of mast cells were depleted, tumor growth inhibition was not 
reversed (Figures 23c and 23d). From this, I concluded that mast cells might not be 









Figure 22. IL-9 does not directly affect the cytotoxicity of CD8+ CTLs.  
Freshly isolated or preactivated Ova-specific CD8+ T cells from OT-I mice were 
cocultured with CFSE-labeled B16F10-Ova in the presence or absence of 
recombinant IL-9 (20 ng ml-1). After 36 h, 7-AAD expression on CFSE+ tumor cells 










Figure 23. Mast cells might not be involved in GITR-induced tumor rejection.  
(a) Expression of mast cell-related enzyme in TdLN of mice received 500 ug ml-1 
control IgG or anti-c-kit (ACK2) at day 2, 5, 8 after tumor inoculation. (b) Number of 
mast cells per area of tumor section is defined by Toluidine blue staining. (c,d) Tumor 
growth curves of individual mice (c) and mean ± s.e.m. values of tumor volume (d) in 
BALB/c mice with s.c. injection of CT26 tumor cells and i.p. administration of DTA-
1 and/or ACK2 (n = 5 or 6). Total rat IgG was used as controls. ** P < 0.01, *** P < 
0.001 by Student’s t test. Data represent two independent experiments. 
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To identify the involvement of DCs, I analyzed maturation status and tumorAg-
presentation capacity of tumor-infiltrating DCs in mice bearing B16F10-Ova. As a 
result, DCs from anti-GITR-treated mice showed more mature phenotypes with high 
expression of CD80, CD86 and MHC class II molecules and were loaded more 
tumorAgs on MHC class I molecules than DCs from control IgG-treated mice. These 
activated phenotypes of DCs were reversed by anti-IL-9 (Figures 24a and 24b). 
Furthermore, functional capacities of infiltrating DCs were also regulated by GITR-
induced IL-9, which was demonstrated by the stimulating capacity to induce IFN-γ 
and IL-2 production from Ova-specific CD8+ CTLs (Figure 24c). Taken together, 
these results indicate that GITR-induced IL-9 exerts the antitumor activity through the 











Figure 24. IL-9 induced by anti-GITR facilitates DC maturation and tumorAg 
cross-presentation. 5-day established B16F10-Ova tumor-bearing mice were 
received control IgG or DTA-1. Anti-IL-9 was administered at day 5, 7, 9 after tumor 
inoculation. (a) Expression of CD80, CD86, MHC class II molecule and Ova-loaded 
MHC class I molecule on tumor-infiltrating DCs isolated 7 days after control IgG or 
DTA-1 treatment. (b) Arbitrary mean fluorescence intensity (MFI) values of indicated 
markers are depicted. (c) IFN-γ and IL-2 production from Ova-specific CD8+ T cells 
cocultured with tumor DCs isolated as above described for 2d. * P < 0.05, ** P < 0.01 




Despite their capacity to induce strong antitumor activity, the underlying mechanisms 
of GITR agonists have been incompletely understood. Our findings demonstrate that 
GITR stimulation mediates the antitumor activity by inducing TH9 differentiation, 
because (i) the major source of IL-9 after anti-GITR treatment was CD4+ T cells and 
anti-IL-9 incapacitated the antitumor activity of anti-GITR, (ii) IL-9 augmented the 
effector function of tumor-specific CTLs that eradicated tumors, (iii) GITR 
stimulation enhanced TH9 differentiation in a T cell-intrinsic manner by activating the 
TRAF6-NF-κB pathway, (iv) GITR stimulation significantly impaired the generation 
and maintenance of iTreg cells in vitro and in tumor-bearing animals. Hence, the 
present study has revealed cellular and molecular mechanisms by which GITR 
agonists promote tumor regression, and provided a fundamental rationale for the use 
of GITR agonists for treating cancer. 
Although the potential role of TH1 or CTL responses in mediating GITR agonists-
induced tumor rejection has been proposed10,11,13, whether TH2 or TH9 cells are 
involved in this process has been poorly understood. This is partially because TH2 
responses are considered to be pro-tumorigenic by inhibiting TH1 differentiation and 
by inducing tolerogenic macrophages48. However, IL-4 has been shown to directly 
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activate NK cells49 and TH2 cells eradicate CTL-resistant tumors by recruiting 
eosinophils50,51, suggesting that type 2 immunity can exert antitumor activity. In the 
present study, the antitumor activity of anti-GITR was almost incapacitated in Il4ra-/- 
mice. Neutralization and adoptive transfer studies revealed that TH9 cells rather than 
TH2 cells were responsible for the IL-4Ra-dependent activation of antitumor 
immunity by anti-GITR. Although GITR ligation remarkably upregulated IL-4 
production by CD4+ T cells, GITR-mediated TH9 differentiation was likely 
independent of autocrine IL-4. However, I also observed that tumor-bearing Il4ra-/- 
mice had considerably reduced IL-9 and that IL-9 production by CD4+ T cells in 
response to anti-GITR in vitro was moderately decreased in the absence of IL-4Ra. 
Thus, I propose that anti-GITR can trigger the differentiation of TH9 cells in the 
absence of endogenous IL-4, but augmented IL-4 production upon GITR stimulation 
might be important for the optimal expression of IL-9. Furthermore, GITR signaling 
shares a common pathway with OX40 via TRAF6-NF-κB to enhance TH9 
differentiation34. However, there might be another distinct pathway triggered by GITR, 
because GITR stimulation significantly induced IL-9+IL-13+ T cells compared to 
OX40 stimulation (Figure 8b) 
A subpopulation of innate lymphoid cells (ILCs) has recently been shown as another 
cellular source of IL-9 in type 2-associated disease models including papain-induced 
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asthma52 and helminth infection53. In the present study, I concluded that the major 
source of IL-9 in mice given anti-GITR is CD4+ T cells, since non-CD4 cells 
produced little IL-9. Moreover, I observed that adoptive transfer of TH9 cells alone 
was sufficient to inhibit tumor growth. Based on these findings I could propose that 
TH9 cells rather than IL-9-producing innate immune cells including ILCs were the 
main effector cell type responsible for the observed IL-9-dependent tumor regression 
in response to anti-GITR.  
GITR costimulation polarizes CD4+ T cells to specialized TH subsets exerting strong 
antitumor activity, those are IL-9+ and IL-9+IL-13+ cells. As described in my results, 
IL-9-secreting TH9 cells have superior tumoricidal potency and TH2 cells also have a 
tumor-regressive effect. Thus, in vivo GITR ligation can initiate tumor regression by 
converting CD4+ T cells into theses antitumor TH cells. For optimizing the 
differentiation to these cells, non-established cell status and appropriate cytokine 
milieu must be equipped, as shown that established Treg cells are more resistant to 
convert into IL-9-producing T cells than naïve T cells and it needs TGF-β plus IL-4. 
From this result, I presumed that the administration of anti-GITR before tumorAg-
activated CD4+ T cells are firmly established would be great for the optimization of 
antitumor effects. 
The pro-tumorigenic function of Treg cells has been well-documented20. In anti-GITR-
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treated tumor bearing mice, the frequency of Foxp3+ cells among tumor-infiltrating 
CD4+ T cells was significantly diminished, which might be due to the inhibition of Treg 
cell generation and/or maintenance. The finding that GITR costimulation obstructed 
the differentiation of iTreg cells and instead converted these cells into TH9 cells 
strongly supports this possibility. In addition, anti-GITR significantly diminished the 
expression of Foxp3 in tumor-specific iTreg cells in vivo. Treg cells in inflammatory 
conditions such as autoimmune diseases and vivaciously proliferating Treg cells are 
known to easily lose Foxp3 expression and divert to exTreg cells54. Although the tumor 
microenvironment is favorable for inducing and maintaining Treg cells, our findings 
suggest that anti-GITR can reverse the Treg cell favorable environment, presumably by 
directly stimulating GITR on Treg cells in mice. Hereby, GITR ligation not only 
activates antitumor immune responses through promoting TH9 differentiation, but also 
contributes to break the tumor-induced suppressive microenvironment through 
inhibiting tumor-specific iTreg integrity. I also observed that anti-hGITR suppressed 
the development of human iTreg cells; however, this treatment did not induce IL-
9+Foxp3- T cells in human system. The reason for this discrepancy between mouse 
and human system is unclear at this stage. Further studies will be needed to dissect the 
underlying mechanisms by which GITR signaling impacts the generation and 
maintenance of tumor-associated Treg cells in humans. 
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In a recent report, the opposing role for IL-9 in antitumor immunity is proposed on the 
basis that IL-9 could promote the suppressive function of Treg cells55. However, I 
observed that Treg cells in IL-9-sufficient hosts induced by anti-GITR slightly or rarely 
altered their suppressive function. Although sort of changes in Treg function could 
occur, effector functions seemed to outdo Treg suppression in status of anti-GITR 
treatment, and consequently eradicate tumors. 
How do IL-9 or TH9 cells exert antitumor immunity? Our findings indicate that anti-
GITR induced tumor-specific CD8+ CTL responses via a mechanism depending on 
IL-9. IL-9 seems to have no direct effect on the cytotoxicity of CD8+ T cells, because 
addition of this cytokine in vitro did not impact their killing activity, indicating that 
other intermediaries mediate the antitumor activity of IL-9. Accordingly, I identified 
that DCs, not mast cells, mediate IL-9-induced antitumor immunity triggered by anti-
GITR. GITR-induced IL-9 enhanced maturation and tumorAg cross-presentation 
capacity of infiltrating DCs in vivo; however, IL-9 also has no direct effect on DCs 
(Figure 25). Therefore, future studies focused on understanding the mechanisms of 







Figure 25. IL-9 has no direct effect on DC activation. Freshly isolated DCs or 
purified bone marrow-derived DCs (BMDCs), derived from the culture of bone 
marrow cells plus GM-CSF for up to 8d, were non-stimulated or stimulated for 24 h 
with LPS (0.5 µg ml-1) or GM-CSF (20 ng ml-1), with or without recombinant IL-9 
(10 ng ml-1). The expression of CD80 and CD86 was analyzed by flow cytometry. 
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In summary, the present study has unveiled that GITR-TRAF6-NF-κB pathway 
potentiates the differentiation of TH9 cells which facilitate antitumor cytotoxic T cell 
responses with maturation of tumor-infiltrating DCs (Figure 26). Our findings reveal 
a novel mechanism of TH9 cell differentiation mediated by GITR costimulation and 
provide a fundamental basis for the use of GITR agonists as a therapeutic strategy for 


















Figure 26. A schematic illustration of the cascade of antitumor immune responses 
induced by anti-GITR.  
Anti-GITR promotes the differentiation of TH9 cells rather iTreg cells and TH9 cell-
derived IL-9 enhances the maturation and tumorAg cross-presentation of infiltrating 
DCs and leads to the differentiation of IFN-γ-, TNF-α- and Granzyme-B-producing 
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  최근 CTLA-4나 PD-1과 같은 T 세포를 자극하는데 있어 check 
point와 같은 역할을 하는 분자의 저해 단클론 항체가 항암 임상 치료에 
있어서 좋은 결과를 내고 있다. GITR는 이와는 반대 역할을 하는 공동 자
극 분자로써 또한 항암 치료에 있어 전도유망한 타겟이 되고 있다. 실제로 
이를 자극하는 단클론 항체가 다양한 마우스 암 모델에서 항암 효과를 지
니고 있음이 확인되었고, 항암 치료제로써 임상 1상이 진행 중에 있다. 이 
항암 효과의 작용 기전에 있어서 많은 연구들이 진행되었고 그 결과 
CD4+ T 세포와 CD8+ T 세포가 중요하다는 결과와 일부에서는 NK/NKT 
세포 혹은 B 세포가 중요하다는 결과들이 있었으나 아직까지 정확한 기전
에 대해서는 불분명한 부분이 많다. 본 연구에서는 이러한 GITR 자극 항
체의 항암 효과에 있어서 IL-9이 중요한 역할을 한다는 것을 밝혀내었다. 
먼저 IL-4 수용체 결함 마우스에서 GITR 자극 항체의 항암 효과가 사라
지는 것을 관찰하였으며, 이 마우스 체내에는 IL-9의 양이 크게 저하되어 
있었다. 실제로 GITR 자극 항체는 마우스 암 모델에서 체내 CD4+ T 세
포로부터 IL-9의 양을 크게 증가시켰으며, 이를 중화 시 항암 효과가 저
하됨을 보여주었다. 또한, GITR 자극은 직접적으로 CD4+ T 세포에서 
TRAF6-NF-κB 경로의 분자적 기전을 통하여 IL-9을 생산함을 밝혀
내었다. 뿐만 아니라 CD4+ T 세포의 GITR 자극 시 암 성장을 촉진할 수 
 73
있는 조절 T 세포로의 분화를 막을 수 있음을 확인하였다.  
  추가적으로 GITR 자극에 의해 생성된 IL-9 의 항암 효과에 대한 
세포적 기전을 확인하였다. IL-9 에 의한 항암 효과의 조절은 세포 독성 
T 세포 반응이 연관되어 있음을 밝혀내었으며, 이는 IL-9 이 체내 수지상 
세포의 성숙 및 암 항원 제시 능을 향상시킴으로써 일어나고, 결과적으로 
세포 독성 T 세포의 작용을 통해 암 성장을 저해할 수 있음을 확인하였다. 
따라서 본 연구를 통해 IL-9 생성 T 세포의 분화에 있어서 GITR 
자극의 역할을 최초로 밝혀내었을 뿐만 아니라 GITR 자극 항체의 정확한 
항암 효과 작용 기전을 밝혀냈다는데 의의가 있다.  
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